Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Опыт успешного применения аутологичной трансплантации стволовых гемопоэтических клеток у пациенток с неблагоприятным прогнозом течения диффузной формы системной склеродермии. / Mazurov, Vadim I.; Maslyanskiy, Alexey L.; Zotkina, Kira E.; Benevolenskaya, Stanislava S.; Motorin, Dmitry V.; Zaritskiy, Andrey Yu; Vasilenko, Elizaveta A.; Vasilenko, Alexey A.; Titova, Anna M.
в: Nauchno-Prakticheskaya Revmatologiya, Том 60, № 3, 10.07.2022, стр. 381-387.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Опыт успешного применения аутологичной трансплантации стволовых гемопоэтических клеток у пациенток с неблагоприятным прогнозом течения диффузной формы системной склеродермии
AU - Mazurov, Vadim I.
AU - Maslyanskiy, Alexey L.
AU - Zotkina, Kira E.
AU - Benevolenskaya, Stanislava S.
AU - Motorin, Dmitry V.
AU - Zaritskiy, Andrey Yu
AU - Vasilenko, Elizaveta A.
AU - Vasilenko, Alexey A.
AU - Titova, Anna M.
N1 - Publisher Copyright: © 2022 Ima-Press Publishing House. All rights reserved.
PY - 2022/7/10
Y1 - 2022/7/10
N2 - One of the methods of treating severe forms of systemic scleroderma is hematopoietic stem-cell autotransplantation (auto-HSCT). The article describes two clinical cases of auto-HSCT followed by rituximab (RTM) therapy in patients with diffuse systemic scleroderma with progressive interstitial lung disease (ILD), high immunological activity, high skin score, and an unfavorable prognosis. The assessment of the course of these diseases was carried out in the course of dynamic observation of patients for 10–11 years. In all cases, auto-HSCT followed by RTM made it possible to achieve remission / low activity, as well as to stabilize the progressive of ILD.
AB - One of the methods of treating severe forms of systemic scleroderma is hematopoietic stem-cell autotransplantation (auto-HSCT). The article describes two clinical cases of auto-HSCT followed by rituximab (RTM) therapy in patients with diffuse systemic scleroderma with progressive interstitial lung disease (ILD), high immunological activity, high skin score, and an unfavorable prognosis. The assessment of the course of these diseases was carried out in the course of dynamic observation of patients for 10–11 years. In all cases, auto-HSCT followed by RTM made it possible to achieve remission / low activity, as well as to stabilize the progressive of ILD.
KW - autologous bone marrow transplantation
KW - interstitial lung disease
KW - systemic scleroderma
KW - autologous bone marrow transplantation
KW - interstitial lung disease
KW - systemic scleroderma
UR - http://www.scopus.com/inward/record.url?scp=85135241784&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/b66224c9-e7f3-3c69-aa5b-935e99899bb8/
U2 - 10.47360/1995-4484-2022-381-387
DO - 10.47360/1995-4484-2022-381-387
M3 - статья
VL - 60
SP - 381
EP - 387
JO - НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ
JF - НАУЧНО-ПРАКТИЧЕСКАЯ РЕВМАТОЛОГИЯ
SN - 1995-4484
IS - 3
ER -
ID: 100703938